Humulin 70/30 is a drug owned by Eli Lilly And Co. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humulin 70/30's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(4 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humulin 70/30's patents.
Latest Legal Activities on Humulin 70/30's Patents
Given below is the list of recent legal activities going on the following patents of Humulin 70/30.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2019 | US7291132 |
| Post Issue Communication - Certificate of Correction | 09 Sep, 2008 | US7291132 |
| Post Issue Communication - Certificate of Correction | 23 Jun, 2008 | US7291132 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Nov, 2007 | US7291132 |
| Recordation of Patent Grant Mailed Critical | 06 Nov, 2007 | US7291132 |
| Email Notification Critical | 19 Oct, 2007 | US7291132 |
| Issue Notification Mailed Critical | 17 Oct, 2007 | US7291132 |
| Dispatch to FDC | 04 Oct, 2007 | US7291132 |
| Application Is Considered Ready for Issue Critical | 01 Oct, 2007 | US7291132 |
| Issue Fee Payment Received Critical | 28 Sep, 2007 | US7291132 |
US patents provide insights into the exclusivity only within the United States, but Humulin 70/30 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humulin 70/30's family patents as well as insights into ongoing legal events on those patents.
Humulin 70/30's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Humulin 70/30's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 09, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Humulin 70/30 Generics:
There are no approved generic versions for Humulin 70/30 as of now.
Alternative Brands for Humulin 70/30
There are several other brand drugs using the same active ingredient (Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human) as Humulin 70/30. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Lilly |
|
About Humulin 70/30
Humulin 70/30 is a drug owned by Eli Lilly And Co. Humulin 70/30 uses Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human as an active ingredient. Humulin 70/30 was launched by Lilly in 1989.
Approval Date:
Humulin 70/30 was approved by FDA for market use on 25 April, 1989.
Active Ingredient:
Humulin 70/30 uses Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human as the active ingredient. Check out other Drugs and Companies using Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human ingredient
Dosage:
Humulin 70/30 is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30 UNITS/ML;70 UNITS/ML | INJECTABLE | Over the counter | INJECTION |